Parkinsonism
For patient information click here
|
WikiDoc Resources for Parkinsonism |
|
Articles |
|---|
|
Most recent articles on Parkinsonism Most cited articles on Parkinsonism |
|
Media |
|
Powerpoint slides on Parkinsonism |
|
Evidence Based Medicine |
|
Clinical Trials |
|
Ongoing Trials on Parkinsonism at Clinical Trials.gov Clinical Trials on Parkinsonism at Google
|
|
Guidelines / Policies / Govt |
|
US National Guidelines Clearinghouse on Parkinsonism
|
|
Books |
|
News |
|
Commentary |
|
Definitions |
|
Patient Resources / Community |
|
Patient resources on Parkinsonism Discussion groups on Parkinsonism Patient Handouts on Parkinsonism Directions to Hospitals Treating Parkinsonism Risk calculators and risk factors for Parkinsonism
|
|
Healthcare Provider Resources |
|
Causes & Risk Factors for Parkinsonism |
|
Continuing Medical Education (CME) |
|
International |
|
|
|
Business |
|
Experimental / Informatics |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
Parkinsonism (also known as Parkinson's syndrome, atypical Parkinson's, or secondary Parkinson's) is a neurological syndrome characterized by tremor, hypokinesia, rigidity, and postural instability.[1] The underlying causes of parkinsonism are numerous, and diagnosis can be complex.[2] While the neurodegenerative condition Parkinson's disease (PD) is the most common cause of parkinsonism, a wide-range of other etiologies can lead to a similar set of symptoms, including some toxins, a few metabolic diseases, and a handful of non-PD neurological conditions.[3] Its most common cause is as a side effect of medications, mainly neuroleptic antipsychotics especially the phenothiazines (such as perphenazine and chlorpromazine), thioxanthenes (such as flupenthixol and zuclopenthixol) and butyrophenones (such as haloperidol (Haldol)), piperazines (such as ziprasidone), and rarely, antidepressants.
Differential Diagnosis
If PD has been excluded, the differential diagnosis or list of potential causes for this syndrome includes:
- AIDS can sometimes lead to the symptoms of Parkinson's disease, due to commonly causing dopaminergic dysfunction.[4]
- Corticobasal degeneration[1]
- Creutzfeldt-Jakob disease[5]
- Diffuse Lewy body disease[1]
- Drug-induced parkinsonism (due to drugs such as antipsychotics, metoclopramide, MPTP[6])[1]
- Encephalitis lethargica[1]
- Multiple system atrophy[7]
- Pantothenate kinase-associated neurodegeneration (Hallervorden-Spatz syndrome)[8]
- Progressive supranuclear palsy[1]
- Toxicity due to substances such as carbon monoxide,[9] carbon disulfide,[9] manganese,[9] paraquat,[10] hexane, rotenone, and toluene.
- Vascular parkinsonism[11]
- Wilson's disease is a genetic disorder in which there is an abnormal accumulation of copper. The excess copper can lead to the formation of a copper-dopamine complex, which leads to the oxidation of dopamine to aminochrome.[12]
- Paraneoplastic syndrome. Neurological symptoms caused by antibodies associated with various cancers.
References
- ↑ 1.0 1.1 1.2 1.3 1.4 1.5 Aminoff MJ, Greenberg DA, Simon RP (2005). Clinical Neurology (6th ed. ed.). Lange: McGraw-Hill Medical. pp. 241&ndash, 5. ISBN 0071423605.
- ↑ Tuite PJ, Krawczewski K (2007). "Parkinsonism: a review-of-systems approach to diagnosis". Seminars in neurology. 27 (2): 113–22. doi:10.1055/s-2007-971174. PMID 17390256.
- ↑ Christine CW, Aminoff MJ (2004). "Clinical differentiation of parkinsonian syndromes: prognostic and therapeutic relevance". Am. J. Med. 117 (6): 412–9. doi:10.1016/j.amjmed.2004.03.032. PMID 15380498.
- ↑ Tse W, Cersosimo MG, Gracies JM; et al. (2004). "Movement disorders and AIDS: a review". Parkinsonism Relat. Disord. 10 (6): 323–34. doi:10.1016/j.parkreldis.2004.03.001. PMID 15261874.
- ↑ Maltête D, Guyant-Maréchal L, Mihout B, Hannequin D (2006). "Movement disorders and Creutzfeldt-Jakob disease: a review". Parkinsonism Relat. Disord. 12 (2): 65–71. doi:10.1016/j.parkreldis.2005.10.004. PMID 16364674.
- ↑ Watanabe Y, Himeda T, Araki T (2005). "Mechanisms of MPTP toxicity and their implications for therapy of Parkinson's disease" (PDF). Med. Sci. Monit. 11 (1): RA17–23. PMID 15614202.
- ↑ Wenning GK, Geser F (2003). "Multiple system atrophy". Rev. Neurol. (Paris). 159 (5 Pt 2): 3S31–8. PMID 12773886.
- ↑ Uc EY, Rodnitzky RL (2003). "Childhood dystonia". Seminars in pediatric neurology. 10 (1): 52–61. doi:10.1016/S1071-9091(02)00010-4. PMID 12785748.
- ↑ 9.0 9.1 9.2 DeLong MR, Juncos JL (2004). Parkinson's Disease and Other Movement Disorders. In: Harrison's Principles of Internal Medicine (16th ed. ed.). McGraw-Hill Professional. pp. p. 2414. ISBN 0-07-140235-7.
- ↑ Dinis-Oliveira RJ, Remião F, Carmo H; et al. (2006). "Paraquat exposure as an etiological factor of Parkinson's disease". Neurotoxicology. 27 (6): 1110–22. doi:10.1016/j.neuro.2006.05.012. PMID 16815551.
- ↑ Thanvi B, Lo N, Robinson T (2005). "Vascular Parkinsonism--an important cause of parkinsonism in older people" (PDF). Age and ageing. 34 (2): 114–9. doi:10.1093/ageing/afi025. PMID 15713855.
- ↑ Członkowska A, Tarnacka B, Möller JC; et al. (2007). "Unified Wilson's Disease Rating Scale - a proposal for the neurological scoring of Wilson's disease patients". Neurol. Neurochir. Pol. 41 (1): 1–12. PMID 17330175.